The Trump administration has made drastic cuts to federal programs that protect the health of Americans, putting women’s health at particular risk. Job cuts described as a “bloodbath,” along with restructuring within the U.S. Department of Health and Human Services (HHS), will dismantle programs that support women’s health, including those that focus on chronic and infectious disease, injuries, mental health, genetic disorders, substance use, and health disparities. These cuts will scale back efforts to prevent, treat, and discover cures for illnesses and diseases, including many that affect women’s reproductive health.
Tuesday, July 29, 2025
Saturday, September 9, 2023
5 facts to know about Medicare drug price negotiation
For far too long, pharmaceutical companies have set astronomically high prescription drug prices in the United States, resulting in millions of Americans being unable to access the medications they need. In 2023, more than 80 percent U.S. adults believe the cost of prescription drugs is unreasonable, with roughly 1 in 3 older Americans reporting that they cannot afford to take their medications as prescribed. The Inflation Reduction Act empowered the secretary of Health and Human Services (HHS), for the first time, to directly negotiate prices for select Medicare drugs. On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Medicare Part D drugs that will be subject to price negotiation, with negotiated prices to take effect in 2026.
Friday, April 3, 2020
How the Trump administration’s deregulation agenda has worsened the coronavirus pandemic
As the United States braces to combat a public health crisis and a severe economic downturn, it is important to note that the Trump administration’s policies have contributed to this crisis. Three years of deregulation under the Trump presidency and a botched response to the COVID-19 pandemic have in part spurred what may be one of the costliest public health crises in American history—both financially and in terms of human life. This column breaks down four of the Trump administration’s deregulatory actions that have worsened the impacts of the coronavirus pandemic.
